View of Current clinical outcome of CD19/CD22 dual-targeting CAR T-cell therapy in refractory or relapsed B-cell acute lymphoblastic leukemia

Return to Article Details Current clinical outcome of CD19/CD22 dual-targeting CAR T-cell therapy in refractory or relapsed B-cell acute lymphoblastic leukemia Download Download PDF